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image before transpulmonary radiofrequency ablation (RFA) reveals
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delayed  complications  were  seen  on  follow-up  chest  and
abdominal  CT  imaging  (Fig.  4).
Figure 2. A CT-ﬂuoroscopic image during RFA shows that aLETTER /Oncology
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Dear  Editor
It  is  usually  difﬁcult  and  hesitant  to  perform  percu-
taneous  radiofrequency  ablation  (RFA)  of  hepatocellular
carcinoma  (HCC)  contiguous  to  the  heart.  Herein,  we
describe  a  case  of  a  HCC  contiguous  to  the  heart  treated
by  transpulmonary  RFA,  after  having  received  transcatheter
arterial  chemoembolization  (TACE).
Case  report
A  71-year-old  woman  with  liver  cirrhosis  was  referred  to  our
department  for  the  treatment  of  HCC.  She  had  undergone
RFA  and/or  TACE  twice  for  multiple  HCCs.  On  follow-
up,  dynamic  computed  tomography  (CT)  revealed  an  HCC,
measuring  18  mm,  in  segment  IV.  This  tumor  was  located
contiguous  to  the  right  atrium  (Fig.  1)  and  undetectable  by
ultrasonography.  She  opted  for  combined  RFA  with  TACE  as
treatment.
TACE  was  performed  with  an  injection  of  a  mixture  of
0.9  mL  iodized  oil  (Lipiodol;  Guerbet,  Villepinte,  France),
0.6  mL  iodized  contrast  material,  and  12  mg  epirubicin,  fol-
lowed  by  gelatin  sponge  particles,  from  the  right  inferior
phrenic  artery.  Next,  RFA  was  performed  7  days  after  TACE.
She  was  placed  in  the  supine  position  and  CT  images  were
obtained  to  verify  the  tumor  location  and  to  determine  the
electrode  trajectory.  After  local  anesthesia,  a  17-gauge  sin-
gle  internally  cooled  electrode  with  a  3-cm  non-insulated
tip  (Cool-tip;  Covidien,  Mansﬁeld,  MA)  was  advanced  to  the
target  under  CT-ﬂuoroscopy  guidance.  After  being  inserted
into  the  tumor  via  the  transpulmonary  route  (Fig.  2  ),  the
electrode  was  connected  to  a  radiofrequency  (RF)  generator
(CC1;  Covidien)  and  RF  energy  was  applied  for  19  minutes.
The  electrode  length  of  the  transgressed  lung  parenchyma
was  2.8  cm.  The  tumor  temperature  at  the  electrode  tip  was
67 ◦C  after  RF  application.  Immediately  after  RFA,  contrast-
enhanced  CT  images  of  the  lung  and  liver  were  obtained
to  assess  the  procedure  and  no  complications  were  seen
(Fig.  3).
Routine  follow-up  chest  radiograph  obtained  4  hours  after
RFA  showed  a  large  pneumothorax.  Although  she  was  asymp-
tomatic,  a  14-F  chest  tube  was  inserted  and  negative
pressure  of  10  cm  H2O  was  applied  continuously  to  the  tube
for  suction.  No  other  complications  occurred.  This  tube  was
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a hepatocellular carcinoma (HCC) measuring 18 mm in diameter in
egment IV, adjacent to the heart (arrow).
emoved  after  6  days,  and  she  was  discharged  10  days  after
FA  without  any  sequelae.  Twelve  months  after  RFA,  the
umor  had  decreased  in  size,  and  no  local  progression  noradiofrequency electrode penetrates the tumor by the transpul-
onary approach. The visibility of the target tumor increased on
T because of the accumulation of iodized oil after transcatheter
rterial chemoembolization (TACE).
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Figure 3. A contrast-enhanced coronal CT image immediately
after RFA shows an unenhanced area around a treated HCC (arrow)
and ascites caused by previous TACE.
Figure 4. An arterial phase coronal CT Image months after
t
n
D
T
o
s
t
S
h
f
i
u
v
p
u
p
u
i
a
s
c
a
m
t
t
a
a
a
o
u
t
h
k
s
R
e
c
t
p
o
t
i
g
i
t
R
o
s
D
T
c
R
[
[
[
[
[
[
K.  Yabushitab,  K.  Sakaguchib,  S.  Kanazawacranspulmonary RFA shows reduction of the tumor size (arrow) with
o evidence of local progression.
iscussion
here  are  many  risks  and  disadvantages  of  performing  RFA
f  HCCs  contiguous  to  the  heart.  Firstly,  because  of  the  pul-
ation  of  the  heart,  an  RF  electrode  insertion  is  difﬁcult  and
he  inserted  electrode  may  migrate  during  RF  application.
econdly,  accidental  insertion  of  an  RF  electrode  into  the
eart  and  thermal  injury  to  cardiac  components  can  cause
atal  complications  [1].  Thirdly,  a  RF  electrode  is  generally
nserted  via  the  transabdominal  and/or  transhepatic  route
nder  ultrasonography  guidance,  and  using  these  routes  is
ery  difﬁcult  and  dangerous  because  such  tumors  are  often
oorly  visualized  or  undetectable  by  ultrasonography.
Percutaneous  liver  RFA  is  usually  performed  under
ltrasonography  guidance  because  of  the  relative  sim-
licity,  low  cost,  portability,  and  non-radiative  nature  of
ltrasonography.  When  the  target  site  is  poorly  visual-
zed  or  undetectable  by  ultrasonography,  some  modiﬁed
pproaches  [2—4],  such  as  artiﬁcial  pleural  effusion  infu-
ion,  artiﬁcial  ascites  infusion,  and  artiﬁcial  pneumothorax
reation,  are  often  used.  However,  these  methods  require
n  operator  with  extensive  experience.  The  transpul-
onary  approach  under  CT  guidance  is  another  methodLetter
hat  can  be  used  for  an  RF  electrode  insertion  into  liver
umors.
TACE  was  performed  from  the  right  inferior  phrenic
rtery  before  RFA  because  decrease  in  risk  of  bleeding
nd/or  tumor  seeding  caused  by  the  electrode  insertion
nd  increase  in  the  visibility  of  HCC  on  CT  images  because
f  the  accumulation  of  iodized  oil  [5].  Although  HCCs  are
sually  vascularized  by  the  hepatic  artery  or  its  branches,
hey  occasionally  receive  their  arterial  supply  from  extra-
epatic  arteries  [6]. The  right  inferior  phrenic  artery  is  well
nown  as  the  main  extra-hepatic  artery  [6]  and  this  HCC  was
uccessfully  performed  TACE  from  this  artery.  In  CT-guided
FA  of  lung  tumors  contiguous  to  the  heart  or  aorta,  Iguchi
t  al.  [1]  described  that  local  control  of  these  tumors  was
onsiderably  lower  than  that  of  tumors  not  contiguous  to
hese  structures.  They  suspected  that  the  electrode  was  not
laced  sufﬁciently  close  to  these  structures  because  of  fear
f  its  insertion  into  them.  Increase  in  the  visibility  of  our
arget  HCC  was  very  important  to  insert  an  RF  electrode
nto  the  tumor  safely  and  accurately  under  CT-ﬂuoroscopy
uidance.
In  conclusion,  we  have  reported  a  successful  outcome
n  a  patient  with  a  single  HCC  adjacent  to  the  heart  and
he  inferior  vena  cava  that  was  treated  by  transpulmonary
FA  7  days  after  TACE.  However,  these  favorable  results
bserved  in  a  single  patient  should  be  validated  by  further
tudies.
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